The cost of unresectable stage III or stage IV melanoma in Italy

Michele Maio, Paolo Ascierto, Alessandro Testori, Ruggero Ridolfi, Emilio Bajetta, Paola Queirolo, Michele Guida, Antonella Romanini, Vanna Chiarion-Sileni, Jacopo Pigozzo, Anna Maria Di Giacomo, Mario Calandriello, Guido Didoni, Marck Van Baardewijk, Cyril Konto, Carlo Lucioni

Research output: Contribution to journalArticlepeer-review

Abstract

Background: In recent decades, melanoma incidence has been increasing in European countries; in 2006, there were approximately 60,000 cases leading to 13,000 deaths. Within Europe there is some geographical variation in the incidence of melanoma, with the highest rates reported in Scandinavia (15 cases per 100,000 inhabitants per year) and the lowest in the Mediterranean countries (5 to 7 cases per 100,000 inhabitants per year). Methods. The present article is based on the information collected in the MELODY study (MELanoma treatment patterns and Outcomes among patients with unresectable stage III or stage IV Disease: a retrospective longitudinal survey).In that study, the medical charts of patients were reviewed to document current treatment patterns and to analyse information on patients, disease characteristics and healthcare resource utilization related to the treatment of advanced melanoma regarding patients who presented with a diagnosis of malignant melanoma (stage I to IV) at participating sites between 01 July, 2005 and 30 June, 2006. Results: Summarizing, though the length of the follow-up period varies among sample patients, an amount of the yearly cost per patient can be estimated, dividing the average per patient total cost (€5.040) by the average follow-up duration (17.5 months) and reporting to one year; on these grounds, unresectable stage III or stage IV melanoma in Italy would cost 3,456 per patient per year.

Original languageEnglish
Article number91
JournalJournal of Experimental and Clinical Cancer Research
Volume31
Issue number1
DOIs
Publication statusPublished - 2012

Keywords

  • Clinical outcomes
  • Medical direct cost
  • Metastatic melanoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint

Dive into the research topics of 'The cost of unresectable stage III or stage IV melanoma in Italy'. Together they form a unique fingerprint.

Cite this